Core Viewpoint - Kangzheng Pharmaceutical (00867) has seen a stock increase of over 3%, currently at 14.47 HKD, with a trading volume of 18.3861 million HKD, following the announcement of its subsidiary, Demy Pharmaceutical, applying for an independent listing on the Hong Kong Stock Exchange and receiving approval for a new drug application for a targeted treatment for vitiligo [1] Group 1: Company Developments - Demy Pharmaceutical, focused on skin health, has received approval from the National Medical Products Administration (NMPA) for the new drug application (NDA) of phosphoric acid ruxolitinib cream for treating non-segmental vitiligo in patients aged 12 and above [1] - The cream is the first and only targeted therapy approved in China for vitiligo, addressing a significant unmet clinical need [1] Group 2: Market Context - According to estimates, approximately 10.3 million people in China suffer from vitiligo, with 8.2 million having non-segmental vitiligo, highlighting a substantial patient population for the new treatment [1] - Current treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical shortcomings, including adverse reactions and limited efficacy with long-term use, indicating a market gap that the new cream could fill [1]
康哲药业涨超3% 机构指芦可替尼乳膏国内获批有望填补白癜风靶向治疗空白